August 28, 2014
GREENWICH, CT and ANN ARBOR, MI — Biotronic, a Great Point Partners I portfolio company and the nation’s leading intraoperative neurophysiology monitoring (“IONM”) company, today announced the promotion of Bill Gecsey, President and CFO, to the position of Chief Executive Officer effective immediately. Mr. Gecsey joined Biotronic in 2010 as CFO, was promoted to President and CFO in 2013 and has been an integral part of Biotronic’s continued growth and success.
“Bill’s efforts and achievements since joining the company in 2010 have been consistently outstanding and have positively impacted every aspect of the business,” said Charles Orsatti, Chairman of the Board of Directors. “Since his promotion to President and CFO last year, his expanded role and responsibilities have directly contributed to the company achieving historical highs in both growth and profitability. We are excited about continuing to work with Bill over the next growth phase for the business.”
Bill Gecsey, CEO of Biotronic, commented “I am honored and excited after four years at Biotronic to become the Chief Executive Officer. I look forward to continuing to build on Biotronic’s commitment to providing the highest quality IONM services in the United States and continuing our trajectory of rapid growth.”
Founded in 1978, Biotronic NeuroNetwork is headquartered in Ann Arbor, Michigan and currently employs over 250 administrative, support and clinical staff, including over 200 technicians throughout the country. Biotronic is the largest independent provider of intraoperative neurophysiological monitoring in the world. www.biotronic.com
About Great Point Partners
Great Point Partners (“GPP”), founded in 2003 and based in Greenwich, CT, is a leading health care investment firm with approximately $800 million of equity capital under management and 26 professionals, investing in the United States, Canada, and Western Europe. GPP is currently making new private equity investments from GPP II, which has closed on $215 million in commitments. Great Point manages capital in private (GPP I, $156 million, and GPP II) and public (BMVF, approximately $370 million) equity funds. Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 100 health care companies. Both the private and public funds invest across all sectors of the health care industry including biologics and pharmaceutical infrastructure, devices and diagnostics, health care services, hospital outsourcing, information technology, and specialty pharmaceuticals. The firm pursues a proactive and proprietary approach to sourcing investments. Reach Great Point at 203-971-3300 or www.gppfunds.com.
This document is intended solely to provide information regarding Great Point Partners’ potential financing capabilities for prospective portfolio companies.